Tempelis L D, Wasik M R, Bortin M M
Ric Clin Lab. 1983 Apr-Jun;13(2):163-82.
The potential role of genetically inappropriate histocompatibility antigens on tumor cells as immunogens and targets for immunotherapy is reviewed. The evidence for immunologic mediation of tumor resistance following individual and pool alloimmunization both in vivo in murine and in vitro in murine and human systems is presented. The antileukemic reaction which follows transplantation of cells from alloimmunized MHC-compatible donors to mice bearing disseminated AKR leukemia is discussed in terms of antigen specificity, effector cell mechanisms and as an immunotherapeutic model. Possible advantages of utilizing cells from MHC-compatible allogeneic donors, rather than from tumor-bearing patients, for immunotherapy of human tumors are discussed. Although many investigators are assessing the significance of alien histocompatibility antigens on cancer cells and the mechanism by which alloimmunization induces antitumor immunity, it remains to be determined whether these efforts will result in an important advance in the treatment of patients with disseminated malignancies.
本文综述了肿瘤细胞上基因不匹配的组织相容性抗原作为免疫原和免疫治疗靶点的潜在作用。文中展示了在小鼠体内以及小鼠和人类系统体外进行个体和混合同种免疫后，肿瘤抗性免疫介导的证据。从抗原特异性、效应细胞机制以及作为一种免疫治疗模型的角度，讨论了将来自同种免疫的MHC相容供体的细胞移植到患有播散性AKR白血病的小鼠体内后所产生的抗白血病反应。文中还讨论了利用MHC相容的同种异体供体而非荷瘤患者的细胞进行人类肿瘤免疫治疗的可能优势。尽管许多研究人员正在评估外来组织相容性抗原对癌细胞的意义以及同种免疫诱导抗肿瘤免疫的机制，但这些努力是否会在播散性恶性肿瘤患者的治疗中取得重要进展仍有待确定。
